The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICLE 2022 | Treating multiple myeloma with cilta-cel in earlier settings
Angela Krackhard, MD, PhD, Technical University of Munich, Munich, Germany, provides her perspectives on the imminent approval of ciltacabtagene autoleucel (cilta-cel), an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma, in Europe. Cilta-cel recognizes two separate epitopes of BCMA, making it a very promising therapy for relapsed/refractory multiple myeloma pretreated with various proteosome inhibitors and antibodies. Prof. Krackhard additionally calls for further studies to assess cilta-cel in earlier lines of therapy to investigate whether they can reduce tumor load to prevent progression. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
